Navigation Links
Oramed Pharmaceuticals to Present at the 70th Scientific Sessions of the American Diabetes Association
Date:6/28/2010

JERUSALEM, June 28, 2010 /PRNewswire-FirstCall/ --

- Results of First Exposure of Type I Diabetes Patients to Oramed's Oral Insulin and of a First-in-Humans Study With its Oral GLP-1 Analog

Oramed Pharmaceuticals, Inc. (OTCBB: ORMP) announced today that its executive management is participating in the 2010 Scientific Sessions of the American Diabetes Association currently being held in Orlando, Florida. Dr. Miriam Kidron, Chief Scientific Officer, is scheduled to present results of two of the company's recently completed clinical trials between 12:00 - 2:00 PM ET on Monday, June 28, 2010 in Poster Hall C at the Orange County Convention Center.

One presentation will provide an overview of the results of a Phase IIa study testing the company's flagship ORMD-0801 oral insulin capsule in Type I diabetes patients when administered just before (10-90 minutes) a standard meal. This first exposure of Oramed's oral insulin established the drug's safety and efficacy in Type I diabetics. ORMD-0801 led to a significant increase in insulin levels in 61% of the treatment sessions, irrespective of the time lapse between ORMD-0801 administration and mealtime. The oral insulin preparation effectively kept glucose levels in check in all sessions. These data suggest both tolerance of Oramed's platform to preprandial dosing regimens and its therapeutic potential in regulating Type I diabetes.

In addition, Dr. Kidron will present a summary of Oramed's first-in-humans clinical trial testing the safety and efficacy of ORMD-0901, an encapsulated oral GLP-1 analog formulation. The study monitored t
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
2. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
3. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
4. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
5. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
6. /K I L L K I L L K I L L -- Oramed Pharmaceuticals Inc./
7. Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository
8. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
9. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
10. Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)
11. Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Valeant Pharmaceuticals International, Inc. (NYSE: ... company,s Bridgewater, New Jersey location ... Drug Administration (FDA) relating to an inspection in June ... Aesthetic injectable, which was divested to Galderma S.A. in ... Valeant,s contract manufacturers (rather than Valeant,s own internal manufacturing) ...
(Date:9/30/2014)... 30, 2014  Based on its recent analysis ... Sullivan recognizes Ventana Medical Systems, Inc. (Ventana), a ... North American Frost & Sullivan Award for Technology ... with a focus on innovation and improving patient ... tissue-based cancer diagnostic solutions for patients worldwide. ...
(Date:9/30/2014)... The report based on "Nutraceutical ... Growth and Forecast, 2007 - 2017," elaborated by Transparency ... billion in 2012 and is further expected to reach ... of 7.3% from 2012 to 2017. Nutraceutical ... especially to prevent chronic diseases that may occur to ...
Breaking Medicine Technology:Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4
... , REDWOOD CITY, Calif., Dec. 15 ... results from five new studies on its Onco type ... currently use to predict the likelihood of chemotherapy benefit and ... were presented at the 32nd Annual CTRC-AACR San Antonio Breast ...
... , , , WALTHAM, Mass., Dec. 15 Decision Resources, ... pharmaceutical and healthcare issues, finds that an overall survival benefit ... European oncologists in their decision to prescribe a novel agent ... The new Special European Physician & Payer Forum report entitled ...
Cached Medicine Technology:Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 2Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 3Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 4Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 5Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 6Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 7For Breast Cancer Treatment, an Agent That Can Achieve an Overall Survival Benefit Would Pose the Greatest Challenge to Avastin's Dominance in Europe 2For Breast Cancer Treatment, an Agent That Can Achieve an Overall Survival Benefit Would Pose the Greatest Challenge to Avastin's Dominance in Europe 3
(Date:9/30/2014)... 30, 2014Levothyroxine (L-T4), long the standard of care ... but some individuals do not regain optimal health ... may help to explain these differences. An expert ... thyroid hormone replacement reviewed the latest studies on ... whether a change to the current standard of ...
(Date:9/30/2014)... at the University of Pittsburgh School of Dental Medicine ... the National Institute of Dental and Craniofacial Research, part ... exploration of the genetic roots of cleft lip and ... populations in Colombia, Nigeria, the Philippines and Pennsylvania. ... the lip or palate that can form when a ...
(Date:9/30/2014)... muscles contain few stem cells, heart tissue is ... Now Tel Aviv University researchers are literally setting ... , Dr. Tal Dvir and his graduate student ... of Materials Science and Engineering, and Center for ... and nanotechnological tools ranging in size from ...
(Date:9/30/2014)... a very valuable procedure by which to screen ... seems that healthy Americans who do undergo this ... before they actually should. Gina Kruse of ... advise that endoscopists stick to the national guidelines ... Journal of General Internal Medicine , published by ...
(Date:9/30/2014)... SIMpalm, the top iPhone app development ... great social networking music sharing experience. Lyricz LLC officially ... and iPod touch®. The App allows users to take ... pre-populated ITunes account. This app also gives users the ... photo of their choice to the snippet of selected ...
Breaking Medicine News(10 mins):Health News:New hypothyroidism treatment guidelines from American Thyroid Association 2Health News:Pitt team searches for genetic roots of cleft lip, palate 2Health News:A heartbeat away? Hybrid 'patch' could replace transplants 2Health News:Americans undergo colonoscopies too often, study finds 2Health News:LYRICZ App for iPhone®, Helps You Share Images with Music to Inspire and Influence 2
... need in ... exploding HSA market, ... an online education, enrollment, and incentive support platform for,Group Health ... Health platform (http://www.fontishealth.com ) simplifies the,administration and use of ...
... The following is a,statement regarding Microsoft,s announcement of ... It is encouraging that companies like Microsoft, Google ... (PHR) products and systems,that people can use to manage ... follow suit. Having ready access to your own,health information ...
... tick-borne illness has nearly tripled, research shows , THURSDAY, Oct. ... fever in the United States almost tripled from 695 in ... fatal disease is caused by Rickettsia rickettsii bacteria, ... dog tick or Rocky Mountain wood tick. Within 14 days ...
... 4, 2007 MedImmune, Inc. today announced results from ... Society of America (IDSA) 45th Annual Meeting adding to ... RSV is a viral pathogen that produces annual ... manifests cold-like symptoms in healthy children, it can prove ...
... General,Dentistry (AGD) was extremely disappointed by President Bush,s ... Program (SCHIP),reauthorization bill. The SCHIP bill agreed upon ... important and beneficial dental,provisions intended to provide for ... Bush, who had threatened to veto this bill,followed ...
... Health Coaching Service,with HealthVault,s Best-Of-Breed Health ... and Compatibility with Other Related Devices,and ... LiveHealthier,announced today the compatibility of its ... HealthVault, the newly launched consumer health,platform. ...
Cached Medicine News:Health News:Fontis Health Launches Online HSA Support System 2Health News:Statement Regarding Microsoft's Announcement of New Services to Help People Store Their Health Information Online 2Health News:Surge in U.S. Cases of Rocky Mountain Spotted Fever 2Health News:Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results 2Health News:AGD Concerned With Presidential Veto of SCHIP Reauthorization Bill 2Health News:AGD Concerned With Presidential Veto of SCHIP Reauthorization Bill 3Health News:LiveHealthier Announces Its Health and Wellness Coaching Solution for Employer Groups is Now Compatible With Microsoft HealthVault 2
Used for the retrieval of stones, stents, or other objects in the urinary tract under direct vision. Retrieval Forceps are designed for use through rigid or flexible endoscopes. Supplied sterile in p...
... technology allows the grasper ... a shorter length and ... the stone. The Unidex ... one-handed operation. Supplied sterile ...
Bugbee Fulgurating...
Fulgurating Electrode, 2 F...
Medicine Products: